

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

NOVO NORDISK INC. and)	
NOVO NORDISK A/S,)	
)	
Plaintiffs,)	C.A. No. 22-856 (CFC)
)	CONSOLIDATED
v.)	ANDA CASE
)	
ORBICULAR PHARMACEUTICAL)	
TECHNOLOGIES PVT. LTD., et al.,)	
)	
Defendants.)	
)	
NOVO NORDISK INC. and)	
NOVO NORDISK A/S,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 23-179 (CFC)
)	ANDA CASE
ORBICULAR PHARMACEUTICAL)	
TECHNOLOGIES PVT. LTD., et al.,)	
)	
Defendants.)	
)	

**STIPULATION AND ~~PROPOSED~~ ORDER OF DISMISSAL OF
CASE NO. 23-179 (CFC)**

WHEREAS Plaintiffs Novo Nordisk, Inc. and Novo Nordisk A/S (“Plaintiffs” or “Novo Nordisk”) and Defendants Orbicular Pharmaceutical Technologies Pvt. Ltd., Cipla Ltd., and Cipla USA, Inc. (“Defendants” or “Orbicular”) are parties to C.A. No. 23-179 (CFC) (the “Action”), which has been consolidated under Lead Case No. 22-856 (CFC), involving United States Patent

Nos. 8,114,833 (the “833 patent”) and 9,265,893 (the “893 patent”) (collectively, the “patents-at-issue”).

NOW THEREFORE, IT IS HEREBY STIPULATED, CONSENTED, AND AGREED, by and between Novo Nordisk and Orbicular, through their undersigned counsel of record, subject to the approval of the Court, that:

(1) Orbicular filed Abbreviated New Drug Application (“ANDA”) No. 217590 (the “Orbicular ANDA”) seeking approval to engage in the commercial manufacture, use, and/or sale of generic liraglutide solution injection in 18 mg/3 ml (6 mg/ml) (“ANDA Product”) before the expiration of the patents-at-issue;

(2) Novo Nordisk filed the Action against Orbicular alleging that Orbicular infringed the patents-at-issue by filing the Orbicular ANDA;

(3) All claims, counterclaims, and affirmative defenses between Novo Nordisk and Orbicular concerning the patents-at-issue are dismissed without prejudice;

(4) Nothing herein prohibits Orbicular from filing and maintaining a Paragraph IV certification to the patents-at-issue in the Orbicular ANDA for the purposes of receiving or maintaining final approval of the Orbicular ANDA, or prevents FDA from granting final approval of the Orbicular ANDA; and

(5) Each party will bear its own attorneys’ fees and costs.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Travis J. Murray

Jack B. Blumenfeld (#1014)
Brian P. Egan (#6227)
Travis J. Murray (#6882)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
began@morrisnichols.com
tmurray@morrisnichols.com

*Attorneys for Novo Nordisk Inc. and
Novo Nordisk A/S*

OF COUNSEL:

Jeffrey J. Oelke
Ryan P. Johnson
Robert E. Counihan
Laura T. Moran
Erica R. Sutter
Olivia L. Wheeling
FENWICK & WEST LLP
902 Broadway, Suite 18
New York, NY 10010-6035
(212) 430-2600

RICHARDS, LAYTON & FINGER, P.A.

/s/ Christine D. Haynes

Kelly E. Farnan (#4395)
Christine D. Haynes (#4697)
One Rodney Square
920 North King Street
Wilmington, DE 19801
(302) 651-7700
farnan@rlf.com
haynes@rlf.com

*Attorneys for Defendants Orbicular
Pharmaceutical Technology Pvt. Ltd.,
Cipla Ltd., and Cipla USA, Inc.*

OF COUNSEL:

William R. Zimmerman
Jonathan E. Bachand
Aryeh N. Feinstein
KNOBBE, MARTENS, OLSON & BEAR, LLP
1717 Pennsylvania Ave. N.W., Ste. 900
Washington D.C. 20006

Joseph M. Reisman, Ph.D.
KNOBBE, MARTENS, OLSON & BEAR, LLP
12790 El Camino Real
San Diego, CA 92130

William O. Adams
Karen M. Cassidy Selvaggio
KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street, 14th Floor
Irvine, CA 92614

Nicholas A. Belair
KNOBBE, MARTENS, OLSON & BEAR, LLP
333 Bush St., 21st Floor
San Francisco, CA 94104

April 11, 2024

SO ORDERED this 11th day of April, 2024.



CHIEF, UNITED STATES DISTRICT JUDGE